Claims for Patent: 5,028,439

Summary for Patent: 5,028,439

Title:	Inhibition of parathyroid hormone secretion
Abstract:	Parathyroid Hormone, when excessively synthesized, induces pathologic bone resorption and demineralization and results in hypocalcemia which produces toxic effects in soft tissues. Non-toxic water-soluble pharmaceutically acceptable compound derivative of peroxydiphosphoric acid, administered orally or systemically, inhibits parathyroid hormone induced bone resorption in vitro and in vivo in warm blooded animals.
Inventor(s):	Gaffar; Abdul (Somerset, NJ)
Assignee:	Colgate Palmolive Company (Piscataway, NJ)
Application Number:	07/296,390
Patent Claims:	1. A method for inhibiting parathyroid hormone induced bone resorption which comprises administering to a warm blooded mammal host having oversecretion of parathyroid hormone a daily dosage of about 0.1-6 grams per kilogram body weight when said administration is oral, or about 0.1-2 grams per kilogram body weight when said administration is systemic, of a non-toxic water soluble pharmaceutically acceptable potassium salt of peroxydiphosphate. 2. The method claimed in claim 1 wherein said peroxydiphosphate compound is present in amount of about 0.1-7% in a pharmaceutical carrier. 3. The method claimed in claim 2 wherein said peroxydiphosphate compound is present in tabletted granules having a coating thereon which is not broken down during passage through the stomach of said warm blooded animal and which coating is dissolved by intestinal fluids having a pH of 5-10. 4. The method claimed in claim 2 wherein said peroxydiphosphate compound is administered to said warm blooded animal in a solution of non-pyrogenic distilled water and sodium chloride buffered with phosphate.

Details for Patent 5,028,439

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2008-07-02